Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients
Clin. transl. oncol. (Print)
; 16(1): 91-95, ene. 2014. tab, ilus
Article
in English
| IBECS
| ID: ibc-127525
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
PURPOSE:
We aimed to determine the efficacy and the toxicity of low dose weekly gemcitabine with radiation therapy in medically unfit muscle-invasive bladder cancer patients.METHODS:
Twenty-six patients were included into the retrospective analysis. Weekly gemcitabine was administered 75 mg/m(2) with a median dose of 63 Gy radiation therapy. Clinical target volume was defined as the urinary bladder only in conformal treatment planning.RESULTS:
Median follow-up was 51 months (range 14-118 months). Complete response rate was 62.5 %. The 5-year local progression-free survival, disease-specific survival and overall survival rates were 40.6, 59.5 and 58.5 %, respectively. Concurrent chemotherapy was continued in 80.7 % of patients without any interruption. Gemcitabine was stopped due to grade 3 thrombocytopenia (n = 1), cardiac angina (n = 1), chronic obstructive pulmonary disease exacerbation (n = 1) or patients' reluctance (n = 2).CONCLUSIONS:
Low dose weekly gemcitabine with concurrent radiotherapy is a tolerable regimen and have comparable outcomes with platinum-based combined treatments in muscle-invasive bladder cancer. Prospective randomized trials can help in understanding the safety and efficacy of this treatment specially in medically unfit patients (AU)RESUMEN
No disponible
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Urinary Bladder Neoplasms
/
Carcinoma, Transitional Cell
/
Chemoradiotherapy
/
Antimetabolites, Antineoplastic
Type of study:
Observational study
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2014
Document type:
Article
Institution/Affiliation country:
Marmara University School of Medicine/Turkey
/
University Pendik Education and Research Hospital/Turkey